带状疱疹感染及芬戈莫德停药后多发性硬化症复发 - Suppr

Suppr

超能文献

Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.

作者信息

Gross Claus Michael, Baumgartner Annette, Rauer Sebastian, Stich Oliver

机构信息

Departments of Neurology, Albert Ludwigs University Freiburg, Germany.

出版信息

Neurology. 2012 Nov 6;79(19):2006-7. doi: 10.1212/WNL.0b013e3182735d24. Epub 2012 Oct 3.

DOI:10.1212/WNL.0b013e3182735d24

PMID:23035074

Abstract

摘要

相似文献

Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.

Neurology. 2012 Nov 6;79(19):2006-7. doi: 10.1212/WNL.0b013e3182735d24. Epub 2012 Oct 3.

Fingolimod and multiple sclerosis: four cautionary tales.

Neurology. 2012 Nov 6;79(19):1942-3. doi: 10.1212/WNL.0b013e3182735edf. Epub 2012 Oct 3.

Rebound of disease activity during pregnancy after withdrawal of fingolimod.

Eur J Neurol. 2013 Aug;20(8):e109-10. doi: 10.1111/ene.12195.

Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.

Arch Dermatol. 2011 Aug;147(8):991-2. doi: 10.1001/archdermatol.2011.212.

Fingolimod for multiple sclerosis.

N Engl J Med. 2012 Jan 26;366(4):339-47. doi: 10.1056/NEJMct1101691.

T-cell response against varicella-zoster virus in fingolimod-treated MS patients.

Neurology. 2013 Jul 9;81(2):174-81. doi: 10.1212/WNL.0b013e31829a3311. Epub 2013 May 22.

Fingolimod: cardiovascular deaths.

Prescrire Int. 2012 Apr;21(126):99.

[Fingolimod treatment in multiple sclerosis].

Nihon Rinsho. 2014 Nov;72(11):2010-4.

Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?

Neurology. 2012 Mar 20;78(12):928-30. doi: 10.1212/WNL.0b013e31824c46ad. Epub 2012 Mar 7.

Cystoid macular edema associated with fingolimod use for multiple sclerosis.

JAMA Ophthalmol. 2013 Jan;131(1):103-7. doi: 10.1001/jamaophthalmol.2013.570.

引用本文的文献

Catalytic Antibodies May Contribute to Demyelination in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Biochemistry. 2024 Jan 2;63(1):9-18. doi: 10.1021/acs.biochem.3c00433. Epub 2023 Nov 27.

Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects.

Front Pharmacol. 2022 Aug 22;13:930615. doi: 10.3389/fphar.2022.930615. eCollection 2022.

Adverse Effects of Immunosuppression: Infections.

Handb Exp Pharmacol. 2022;272:287-314. doi: 10.1007/164_2021_550.

Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

Int J Physiol Pathophysiol Pharmacol. 2020 Jun 15;12(3):88-94. eCollection 2020.

Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.

Neurol Ther. 2019 Dec;8(2):241-250. doi: 10.1007/s40120-019-00160-9. Epub 2019 Nov 1.

Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.

Clin Drug Investig. 2019 Sep;39(9):909-913. doi: 10.1007/s40261-019-00804-6.

Fingolimod Alters Tissue Distribution and Cytokine Production of Human and Murine Innate Lymphoid Cells.

Front Immunol. 2019 Feb 13;10:217. doi: 10.3389/fimmu.2019.00217. eCollection 2019.

Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.

Intern Med. 2018 Sep 15;57(18):2647-2655. doi: 10.2169/internalmedicine.0793-18. Epub 2018 Apr 27.

S1P deletion differentially affects TH17 and Regulatory T cells.

Sci Rep. 2017 Oct 10;7(1):12905. doi: 10.1038/s41598-017-13376-2.

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo.

Mult Scler J Exp Transl Clin. 2017 Sep 27;3(3):2055217317730096. doi: 10.1177/2055217317730096. eCollection 2017 Jul-Sep.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.

Neurology. 2012 Nov 6;79(19):2006-7. doi: 10.1212/WNL.0b013e3182735d24. Epub 2012 Oct 3.

Fingolimod and multiple sclerosis: four cautionary tales.

Neurology. 2012 Nov 6;79(19):1942-3. doi: 10.1212/WNL.0b013e3182735edf. Epub 2012 Oct 3.

Rebound of disease activity during pregnancy after withdrawal of fingolimod.

Eur J Neurol. 2013 Aug;20(8):e109-10. doi: 10.1111/ene.12195.

Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.

Arch Dermatol. 2011 Aug;147(8):991-2. doi: 10.1001/archdermatol.2011.212.

Fingolimod for multiple sclerosis.

N Engl J Med. 2012 Jan 26;366(4):339-47. doi: 10.1056/NEJMct1101691.

T-cell response against varicella-zoster virus in fingolimod-treated MS patients.

Neurology. 2013 Jul 9;81(2):174-81. doi: 10.1212/WNL.0b013e31829a3311. Epub 2013 May 22.

Fingolimod: cardiovascular deaths.

Prescrire Int. 2012 Apr;21(126):99.

[Fingolimod treatment in multiple sclerosis].

Nihon Rinsho. 2014 Nov;72(11):2010-4.

Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?

Neurology. 2012 Mar 20;78(12):928-30. doi: 10.1212/WNL.0b013e31824c46ad. Epub 2012 Mar 7.

Cystoid macular edema associated with fingolimod use for multiple sclerosis.

JAMA Ophthalmol. 2013 Jan;131(1):103-7. doi: 10.1001/jamaophthalmol.2013.570.

引用本文的文献

Catalytic Antibodies May Contribute to Demyelination in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Biochemistry. 2024 Jan 2;63(1):9-18. doi: 10.1021/acs.biochem.3c00433. Epub 2023 Nov 27.

Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects.

Front Pharmacol. 2022 Aug 22;13:930615. doi: 10.3389/fphar.2022.930615. eCollection 2022.

Adverse Effects of Immunosuppression: Infections.

Handb Exp Pharmacol. 2022;272:287-314. doi: 10.1007/164_2021_550.

Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

Int J Physiol Pathophysiol Pharmacol. 2020 Jun 15;12(3):88-94. eCollection 2020.

Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.

Neurol Ther. 2019 Dec;8(2):241-250. doi: 10.1007/s40120-019-00160-9. Epub 2019 Nov 1.

Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.

Clin Drug Investig. 2019 Sep;39(9):909-913. doi: 10.1007/s40261-019-00804-6.

Fingolimod Alters Tissue Distribution and Cytokine Production of Human and Murine Innate Lymphoid Cells.

Front Immunol. 2019 Feb 13;10:217. doi: 10.3389/fimmu.2019.00217. eCollection 2019.

Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.

Intern Med. 2018 Sep 15;57(18):2647-2655. doi: 10.2169/internalmedicine.0793-18. Epub 2018 Apr 27.

S1P deletion differentially affects TH17 and Regulatory T cells.

Sci Rep. 2017 Oct 10;7(1):12905. doi: 10.1038/s41598-017-13376-2.

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo.

Mult Scler J Exp Transl Clin. 2017 Sep 27;3(3):2055217317730096. doi: 10.1177/2055217317730096. eCollection 2017 Jul-Sep.